

## Journal of Pharmaceutical and Biomedical Analysis

### Editors

**J. Haginaka**, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya 663-8179, Japan. E-mail: jpba@ph.mwu.mukogawa-u.ac.jp

**S. Pinzauti**, Department of Pharmaceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019 Sesto Fiorentino, Italy. E-mail: pinz@unifi.it

**J.F. Stobaugh**, Department of Pharmaceutical Chemistry, 2095 Constant Avenue, The University of Kansas, Lawrence, KS 66047, USA. E-mail: jstobaugh@sunflower.com

**I.D. Wilson**, Drug Metabolism and Pharmacokinetics Department, AstraZeneca Pharmaceuticals, Mereside, Aldery Park, Macclesfield, Cheshire SK10 4TG, UK. E-mail: Ian.Wilson@astrazeneca.com

### Editorial Advisory Board

**M.G. Bartlett** (Athens, GA, USA)

**R.G. Bell** (Ozona, FL, USA)

**V. Cavrini** (Bologna, Italy)

**B. Chankvetadze** (Münster, Germany)

**J. Crommen** (Liège, Belgium)

**S. Furlanetto** (Florence, Italy)

**E. Gelpi** (Barcelona, Spain)

**S. Görög** (Budapest, Hungary)

**J. Goto** (Sendai, Japan)

**D.S. Hage** (Nabraska, USA)

**S.H. Hansen** (Copenhagen, Denmark)

**U. Holzgrabe** (Würzburg, Germany)

**S. Honda** (Higashi-Osaka, Japan)

**R. Kaliszan** (Gdansk, Poland)

**K. Karljikovic-Rajic** (Belgrade, Serbia and Montenegro)

**W. Lindner** (Vienna, Austria)

**H. Lingeman** (Amsterdam, The Netherlands)

**C.E. Lunte** (Kansas, USA)

**K. Markides** (Uppsala, Sweden)

**G. Markó-Varga** (Lund, Sweden)

**B.K. Matuszewski** (West Point, PA, USA)

**Y. Michotte** (Brussels, Belgium)

**M.C.B.S.M. Montenegro** (Porto, Portugal)

**D.E. Moore** (Sydney, NSW, Australia)

**E.J. Munson** (Lawrence, KS, USA)

**T. Nakagawa** (Kyoto, Japan)

**K. Nakashima** (Nagasaki, Japan)

**J.K. Nicholson** (London, UK)

**B. Nickerson** (Pawcatuck, CT, USA)

**D.M. Radzik** (Rochester, NY, USA)

**R. Sandulescu** (Cluj-Napoca, Romania)

**T. Santa** (Tokyo, Japan)

**K.E. Scriba** (Jena, Germany)

**A. Shibukawa** (Kyoto, Japan)

**D. Stevenson** (Surrey, UK)

**J.T. Stewart** (Athens, GA, USA)

**S. Terabe** (Hyogo, Japan)

**J.-L. Veuthey** (Geneva, Switzerland)

### Aims and Scope

This journal is an international medium for the publication of original research reports and authoritative reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical and biomedical sciences, including relevant developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focussing on individual groups of drugs, drug stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance and drug-related topics of health and safety in the pharmaceutical industry are welcome.

Since classical spectrophotometric (including derivative spectrophotometry), measurements and applications, solvent extraction, basic electroanalytical methods, titrimetry, etc. are well established, studies in such areas should demonstrate a unique and substantial advantage over presently known systems. Studies reporting such work should also be supported by a demonstration of the application of the method to actual samples. In determining the suitability of submitted articles for publication, particular scrutiny will be placed on the degree of novelty and significance of the research and the extent to which it adds to existing knowledge in pharmaceutical and biomedical analysis. In all submissions to the journal, authors must address the question of how their proposed methodology compares with previously reported methods. A substantial body of work cannot be fractionated into different shorter papers.

The journal is directed towards the needs of academic, clinical, government and industrial analysis and presents a unique forum for the discussion of current developments at the interface between pharmaceutical, biochemical and clinical analysis.

**Publication information:** *Journal of Pharmaceutical and Biomedical Analysis* (ISSN 0731-7085). For 2004 volumes 33, 34 and 35 are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Regional Sales Office nearest you or from this journal's website (<http://www.elsevier.com/locate/jpba>). Further information is available on this journal and other Elsevier products through Elsevier's website: (<http://www.elsevier.com>). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

**Orders, claims, and journal enquiries:** please contact the Customer Service Department at the Regional Sales Office nearest you:

**Orlando:** Elsevier, Customer Service Department, 6277 Sea Harbor Drive, Orlando, FL 32887-4800, USA; phone: (+1) (877) 8397126 [toll free number for US customers], or (+1) (407) 3454020 [customers outside US]; fax: (+1) (407) 3631354; e-mail: [usjcs@elsevier.com](mailto:usjcs@elsevier.com)

**Amsterdam:** Elsevier, Customer Service Department, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) (20) 4853757; fax: (+31) (20) 4853432; e-mail: [nlinfo-f@elsevier.com](mailto:nlinfo-f@elsevier.com)

**Tokyo:** Elsevier, Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: [jp.info@elsevier.com](mailto:jp.info@elsevier.com)

**Singapore:** Elsevier, Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: [asiainfo@elsevier.com](mailto:asiainfo@elsevier.com)

This journal is in the *ADONIS Service*, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to: ADONIS B.V., P.O. Box 993, 1000 AZ Amsterdam, The Netherlands

### GENERAL INFORMATION

A detailed leaflet 'Instructions for Authors' is available from the publisher, Elsevier B.V., P.O. Box 330, 1000 AH Amsterdam, The Netherlands, upon request, and is also published volume 34, issue 5. The instructions can also be found on the World Wide Web: access under <http://www.elsevier.com/locate/jpba>

Contributions which fulfil the Aims and Scope of the journal will be welcomed from anywhere in the world. The language of the journal is English. All manuscripts should be written in the past tense and impersonal style. Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher.

### Manuscript Format

Manuscripts should be type-written on good quality paper conforming to either European A4 size (210 × 297 mm) or US Letter size (8.5 × 11 inches). Manuscripts must be *double-spaced on one side only*, with at least 2.5 cm (1 inch) margins all round and should be submitted *in triplicate*. All pages should be numbered and the first page must contain the following: title; names of all authors with their contact and e-mail addresses in full. The name of the corresponding author should be indicated by an asterisk and their telephone, fax and e-mail address added as a footnote to the first page, which should be followed by the following sections in sequence: *Abstract* (Reviews and Full Papers only); *Keywords*; *Introduction*; *Experimental* (or *Materials and Methods*); *Results*; *Discussion*; *Conclusions*; *Acknowledgement* (s); *References*; *Tables* (each on an individual page with legend); list of *Figure Legends*; *Figures*. Figures and Tables must *not be* included in the body of the text.

### Manuscript Submission

Authors should submit original full-length Research Papers, Short Communications, Reviews, Analytical Surveys and Book Reviews to one of the Editors. Authors are encouraged to submit their paper online by using the Online Submission tool for the Journal of Pharmaceutical and Biomedical Analysis. To submit online authors should upload their article as a *LaTeX*, *Microsoft® (MS)Word®*, *WordPerfect®*, or PostScript via the journal's Author Gateway homepage at <http://authors.elsevier.com/journal/jpba>. Full instructions how to use the online submission tool are available at the online submission website of the journal.

Authors who prefer to submit their manuscript by post should submit **three** hard copies of their paper and a copy of the completed **Author Checklist** (published on the website and in the end-pages of the Journal) to one of the Editors.

The original manuscript and figures will be discarded 1 month after publication, unless the Publisher is requested to return the original material to the author. For detailed instructions on the preparation of electronic artwork, consult Elsevier's Author Gateway at <http://authors.elsevier.com>

**Electronic manuscripts submitted by post.** Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. For the initial submission of manuscripts for consideration, hardcopies are sufficient. For the processing of **accepted papers**, electronic versions are preferred. After **final acceptance**, your disk plus three final and exactly matching printed versions should be submitted together. Floppy disks, ZIP/JAZ disks or CD roms are acceptable. It is important that the file saved is in the native format of the wordprocessor program used. Label the disk with the name of the computer and wordprocessing package used, your name, and the name of the file on the disk. Further information may be obtained from the Publisher.

### Proofs

Proofs must be returned to the Publisher within the time period specified, after which the Editors reserve the right to make any necessary corrections to a paper prior to publication. Only *necessary amendments* will be accepted at this stage and any changes not of a typographical nature may be charged to the Author.

### Reprints

Twenty five reprints of each paper will be sent to the senior author free of charge. Additional copies may be ordered on the form accompanying the proofs.

### Other enquiries

Visit Elsevier's Author Gateway (<http://authors.elsevier.com>) for the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed. The Author Gateway also provides detailed artwork guidelines, copyright information, frequently asked questions and more.

Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

**Authors in Japan please note:** Upon request, Elsevier Japan will provide authors with a list of people who can check and improve the English of their paper (*before submission*). Please contact our Tokyo office: Elsevier, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan, Tel.: (+81) (3) 5561 5032; Fax: (+81) (3) 5561 5045; e-mail: [jp.info@elsevier.com](mailto:jp.info@elsevier.com).

**Advertising information:** Advertising orders and enquiries can be sent to: **USA, Canada and South America:** Mr Tino DeCarlo, The Advertising Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: [t.decarlo@elsevier.com](mailto:t.decarlo@elsevier.com). **Japan:** The Advertising Department, Elsevier K.K., 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: [jp.info@elsevier.com](mailto:jp.info@elsevier.com). **Europe and ROW:** Commercial Sales Department, Elsevier Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 1865 843016; fax: (+44) 1865 843976; e-mail: [media@elsevier.com](mailto:media@elsevier.com)

**USA mailing notice:** *Journal of Pharmaceutical and Biomedical Analysis* (ISSN 0731-7085) is published monthly except semimonthly in February, March, April, August and September by Elsevier B.V. (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA US\$ 2701 (valid in North, Central and South America), including air speed delivery. Application to mail at periodical postage rate is pending at Jamaica, NY 11431.

**USA POSTMASTER:** Send address changes to *Journal of Pharmaceutical and Biomedical Analysis*, Publications Expediting Inc., 200 Meacham Ave, Elmont, NY 11003.

**AIRFREIGHT AND MAILING** in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.

*Journal of Pharmaceutical and Biomedical Analysis* has no page charges

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed in The Netherlands